HLA-DR inhibitors belong to a distinct chemical class of compounds designed to modulate the activity of the HLA-DR protein. HLA-DR, short for Human Leukocyte Antigen-DR, is a pivotal member of the major histocompatibility complex (MHC) class II molecules, playing a crucial role in immune system responses by presenting antigens to immune cells. These inhibitors are carefully crafted molecules tailored to interact with the HLA-DR protein, affecting its normal functioning. Through these interactions, they might influence various cellular processes associated with antigen presentation and immune responses, without directly impacting its binding to specific antigens or its involvement in immune cell interactions.
The design of HLA-DR inhibitors is informed by a deep understanding of the structural and functional attributes of the HLA-DR protein. Advanced chemical synthesis methods and insights from structural biology are commonly employed in the development of these inhibitors. Their notable characteristic lies in their ability to selectively bind to HLA-DR, enabling focused modulation of cellular processes that rely on the participation of this specific MHC class II molecule. Researchers and scientists interested in unraveling the complexities of immune system functioning and antigen presentation often utilize HLA-DR inhibitors as valuable tools. Through systematic experimentation, they can investigate how the inhibition of HLA-DR influences various cellular processes, thereby contributing to a deeper understanding of its involvement in diverse immunological and cellular contexts. The development and utilization of HLA-DR inhibitors contribute to advancing our knowledge of the intricate interplay between immune components and functions, offering insights into the fundamental molecular mechanisms that underlie immune responses and antigen recognition.
Items 1 to 10 of 13 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | ¥632.00 | 1 | |
与氯喹类似,这种药物也会干扰抗原递呈。 | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | ¥338.00 ¥587.00 ¥1376.00 ¥4140.00 | 25 | |
影响细胞中的蛋白转运,可能会抑制 HLA-D 呈递抗原。 | ||||||
Ivermectin | 70288-86-7 | sc-203609 sc-203609A | 100 mg 1 g | ¥632.00 ¥846.00 | 2 | |
伊维菌素通过调节免疫反应来下调HLA-DR的表达。它抑制细胞因子的产生,导致MHC II类表达减少,从而影响抗原呈递。 | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | ¥812.00 ¥1636.00 ¥2990.00 ¥5517.00 ¥15784.00 ¥1117.00 | 19 | |
蛋白酶抑制剂,可影响抗原加工,从而影响 HLA-D 对抗原的表达。 | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | ¥1230.00 ¥3949.00 | 8 | |
沙利度胺通过减少 TNF-α 和 IFN-gamma 等促炎细胞因子的分泌来抑制 HLA-DR 的表达。这会抑制免疫反应,降低 MHC II 类表达,从而影响抗原递呈。 | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | ¥632.00 ¥2933.00 ¥11056.00 | 163 | |
蛋白酶体抑制剂,可干扰抗原处理和表达。 | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | ¥857.00 ¥925.00 ¥4140.00 | 36 | |
地塞米松是一种抑制免疫反应的皮质类固醇。它通过阻断 MHC II 类基因的转录来抑制 HLA-DR 的表达,抑制免疫系统的激活和随后的抗原递呈。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | ¥699.00 ¥1749.00 ¥3610.00 | 233 | |
雷帕霉素通过靶向mTOR通路抑制HLA-DR的表达。它破坏mTOR信号传导,导致MHC II类表达下调,并影响抗原加工和呈递给T细胞。 | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | ¥699.00 ¥1015.00 ¥3373.00 ¥5359.00 ¥11451.00 ¥23681.00 | 69 | |
环孢菌素A通过抑制T细胞活化来抑制HLA-DR的表达。它阻碍钙调神经磷酸酶的活性及其下游NFAT信号传导,从而减少细胞因子生成,这些细胞因子可促进MHC II类表达和抗原呈递。 | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | ¥857.00 ¥1670.00 | 9 | |
FK506通过阻断钙调神经磷酸酶和NFAT激活来抑制HLA-DR的表达,与环孢菌素A类似。它可调节T细胞反应,抑制MHC II类基因表达和抗原呈递所需的细胞因子产生。 |